Skip to main content

Table 1 Patient characteristics (n = 1140)

From: The association of low complement with disease activity in systemic sclerosis: a prospective cohort study

Characteristic n (%) or mean ± SD
Age at diagnosis, years 46.0 ± 14.1
Age at recruitment, years 57.4 ± 12.3
Follow-up duration, years 3.4 ± 1.7
Sex
 Male 148 (13.0 %)
 Female 992 (87.2 %)
Race
 White 1012 (93.3 %)
 Asian 50 (4.7 %)
 Australian Aboriginal or Torres Strait Islander 14 (1.3 %)
 Other 9 (0.9 %)
Disease duration at recruitmenta 11.3 ± 9.9
  ≤ 2 years 163 (14.3 %)
  ≤ 5 years 356 (31.2 %)
Disease subtypeb
 Diffuse 310 (27.2 %)
 Limited 830 (72.8 %)
Overlap disease features present everc 267 (23.4 %)
 Rheumatoid arthritis 22 (1.9 %)
 Polymyositis 6 (0.5 %)
 Dermatomyositis 1 (0.01 %)
 Sjögren’s syndrome 21 (1.8 %)
 SLE 9 (0.8 %)
Serological profile at recruitment
 Anti-centromere ANA 517 (46.2 %)
 Anti-Scl-70 antibodies 167 (15.2 %)
 Anti-RNAP antibodies 84 (13.3 %)
 Anti-U1 RNP antibodies 22 (2.0 %)
 Anti-Ro antibodies 72 (6.6 %)
 Anti-La antibodies 18 (1.6 %)
 Anti-Sm antibodies 6 (0.6 %)
 Anti-PM-Scl antibodies 15 (1.4 %)
 Anti-dsDNA antibodies 26 (3.1 %)
 Anti-Jo-1 antibodies 5 (0.5 %)
 ANCA 134 (12.9 %)
  MPO specificity 17 (1.6 %)
  PR-3 specificity 22 (2.1 %)
 Rheumatoid factor 288 (27.2 %)
 Anti-phospholipid antibodies 272 (25.7 %)
  Cardiolipin IgM 165 (65.0 %)
  Cardiolipin IgG 105 (39.3 %)
 Anti-β2-glycoprotein antibody 84 (33.0 %)
 Lupus anticoagulant 26 (3.1 %)
  1. Abbreviations: ANA Anti-nuclear antibody, Anti-Scl-70 Anti-scleroderma-70 antibodies, Anti-U1 RNP Anti-ribonucleoprotein antibodies, Anti-Sm Anti-Smith antibodies, Anti-PM-Scl Anti-polymyositis scleroderma antibodies, Anti-dsDNA Anti-double-stranded DNA antibodies, Anti-RNAP Anti-RNA polymerase antibodies, ANCA Anti-neutrophil cytoplasmic antibodies, MPO Myeloperoxidase, PR-3 Proteinase-3
  2. aSince onset of first non-Raynaud’s phenomenon disease manifestation
  3. bDisease subtype based on extent of skin involvement, with limited disease being confined to the extremities distal to elbows and knees, as well as the face
  4. cActual overlap disease features specified for only a proportion of patients classified by the treating physician as having ‘SSc overlap syndrome’